Sign in

Private company

IsoPlexis Corp

American laboratory analytical instruments company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a life sciences company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to more directly assess in vivo biology and develop more precise and personalized therapies. We are enabling deeper access to in vivo biology and driving durable and potentially transformational research on disease in a new era of advanced medicine.”42 It is headquartered in Branford, Connecticut.1

Last updated Oct 21, 2026.

Overview

  • IndustryLaboratory Analytical Instruments1
  • HeadquartersBranford, Connecticut1
  • Incorporated inDE2
  • Business address35 Ne Industrial Road, Branford, Ct 064052
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-5.5%Gross margin3
-604.0%Operating margin3
-632.4%Net margin3
-2.9%Revenue growth, 20223
-256.9%Return on equity3
1.12×Debt to equity3
-$104.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$23.5M

Out of $16.8M in revenue.3 The company lost money this year.

Financial statements

Revenue43$16.8M in 2022+61% since 2020
0$5.0M$10.0M$15.0M$20.0M2020: $10.4M$10.4M20202021: $17.3M$17.3M2021+66%2022: $16.8M$16.8M2022−3%
Gross profit43-$925.0K in 2022
-$2.5M0$2.5M$5.0M$7.5M$10.0M2020: $5.4M$5.4M20202021: $8.8M$8.8M2021+62%2022: -$925.0K-$925.0K2022
Operating income43-$101.2M in 2022+271% since 2020
-$150.0M-$100.0M-$50.0M02020: -$27.3M-$27.3M20202021: -$76.3M-$76.3M2021+180%2022: -$101.2M-$101.2M2022+33%
Net income3-$106.0M in 2022+30% since 2020
-$150.0M-$100.0M-$50.0M02020: -$81.6M-$81.6M20202021: -$81.6M-$81.6M2021−0%2022: -$106.0M-$106.0M2022+30%
Fiscal year2019202020212022
Revenue$10.4M4$17.3M3$16.8M3
Gross profit$5.4M4$8.8M3-$925.0K3
Research and development$11.2M4$21.0M3$23.5M3
Operating expenses$85.1M3$100.3M3
Operating income-$27.3M4-$76.3M3-$101.2M3
Net income-$81.6M3-$81.6M3-$106.0M3
Earnings per share-$14.064-$8.993-$2.703
Earnings per share (diluted)-$14.064-$8.993-$2.703
Shares (weighted, basic)10.2M shares339.3M shares3
Shares (weighted, diluted)10.2M shares339.3M shares3

Compare IsoPlexis Corp with another company

Corporate structure

IsoPlexis Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of IsoPlexis Corp

  • IsoPlexis Corp Branford, Connecticut

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IsoPlexis Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$16.1M3 Dec 31, 2022$8.8M3 Dec 31, 2021+83.6%
Accumulated depreciation$4.9M3 Dec 31, 2022$3.0M3 Dec 31, 2021+62.7%
Property and equipment, net$11.2M3 Dec 31, 2022$5.8M3 Dec 31, 2021+94.5%
Operating-lease assets (leased space)$5.1M3 Dec 31, 2022$03 Dec 31, 2021

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$37.5M3 Dec 31, 2022$126.6M3 Dec 31, 2021−70.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$22.7M3 Dec 31, 2022$22.3M3 Dec 31, 2021+2.0%
Accumulated amortization$2.9M3 Dec 31, 2022$1.3M3 Dec 31, 2021+129.2%
Finite-lived intangibles, net$19.8M3 Dec 31, 2022$21.0M3 Dec 31, 2021−5.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$27.5M3 Dec 31, 2022$24.3M3 Dec 31, 2021+13.2%
Raw materials$32.3M3 Dec 31, 2022$22.2M3 Dec 31, 2021+45.8%
Work in process$1.3M3 Dec 31, 2022$03 Dec 31, 2021
Finished goods$3.4M3 Dec 31, 2022$2.5M3 Dec 31, 2021+37.4%

Leadership

Who has led IsoPlexis Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Sean Mackay2021–2023

Chief financial officer

  1. John Strahley2021–2023
2025
Board members and other officers (11)

Timeline

  1. Mar 22, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale19
  2. Mar 16, 20238-K Shareholder vote20
  3. Mar 9, 20238-K Other events21
  4. Feb 16, 20238-K Entered a material agreement22
  5. Jan 12, 20238-K Results of operations23
  6. Dec 21, 20228-K Entered a material agreement; Other events24
  7. Nov 10, 20228-K Results of operations25
  8. Sep 12, 20228-K Regulation FD disclosure26
  9. Aug 23, 20228-K Executive or director change; Regulation FD disclosure27
  10. Aug 10, 20228-K Results of operations28
  11. Jun 21, 20228-K Shareholder vote29
  12. May 11, 20228-K Results of operations30
  13. Oct 7, 2021New chief executive Sean Mackay becomes CEO7

Calendar

When it reported results

  1. Jan 12, 2023Reported quarterly or annual results23
  2. Nov 10, 2022Reported quarterly or annual results25
  3. Aug 10, 2022Reported quarterly or annual results28
  4. May 11, 2022Reported quarterly or annual results30
  5. Apr 11, 2022Reported quarterly or annual results31
  6. Mar 2, 2022Reported quarterly or annual results32
  7. Jan 10, 2022Reported quarterly or annual results33
  8. Nov 10, 2021Reported quarterly or annual results34

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

142 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 20 major events, 60 insider forms, 16 large holders, 40 other. The latest 20:

  1. Jun 15, 2023SC 13D/A EDGAR
  2. Mar 31, 202315-12G EDGAR
  3. Mar 22, 20238-K EDGAR
  4. Mar 21, 2023S-8 POS EDGAR
  5. Mar 21, 2023S-8 POS EDGAR
  6. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  7. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  8. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  9. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  10. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  11. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  13. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  14. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  15. Mar 21, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  16. Mar 16, 2023425 EDGAR
  17. Mar 16, 2023425 EDGAR
  18. Mar 16, 20238-K EDGAR
  19. Mar 14, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Mar 9, 2023DEFA14A EDGAR

The 142 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2022SHAMIR NACHUMDirectorBuy40,000$1.94$77.6KForm 4
Aug 30, 2022SHAMIR NACHUMDirectorBuy10,253$1.89$19.4KForm 4
Aug 25, 2022Strahley JohnChief Financial OfficerBuy10,000$2.00$20.0KForm 4
Aug 25, 2022Mackay SeanChief Executive OfficerBuy15,000$1.99$29.9KForm 4
Aug 25, 2022Rew Richard W. IISVP, GC and SecretaryBuy20,000$1.99$39.8KForm 4
Oct 12, 2021Northpond Ventures, LP10% ownerBuy1,000,000$15.00$15.0MForm 4
Oct 12, 2021EDELMAN JOSEPH10% ownerBuy850,000$15.00$12.8MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How IsoPlexis Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIsoPlexis Corp1
  • CIK0001615055
  • Employer ID (EIN)46-21797991
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3826 Laboratory Analytical Instruments1
  • Business address35 Ne Industrial Road, Branford, CT 064051
  • Phone203-208-41111
  • Shares outstanding39,763,101 as of Feb 27, 20233
  • Public float$13.2M as of Jun 30, 20223
  • On EDGAR sinceJul 29, 20141
  • Filings165 in all: 4 (41), 425 (20), 8-K (20), 3 (18), D (7), SC 13G/A (7), SC 13G (6), CORRESP (5)1
    All 33 form types

    10-Q (4), DEFA14A (3), S-1/A (3), SEC STAFF LETTER (3), UPLOAD (3), 10-K (2), DRSLTR (2), S-8 (2), S-8 POS (2), SC 13D/A (2), 15-12G (1), 25-NSE (1), 424B4 (1), 5 (1), 8-A12B (1), CERT (1), DEF 14A (1), DEFM14A (1), DEFR14A (1), DRS (1), DRS/A (1), EFFECT (1), S-1 (1), SC 13D (1), SD (1)

  • Latest filingsAnnual report (10-K) Mar 2, 2023
    Quarterly report (10-Q) Nov 10, 2022
    Proxy statement (DEF 14A) Apr 27, 2022
    Latest 8-K (8-K) Mar 22, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42